Nucor earnings beat by $0.08, revenue fell short of estimates
Chimerix Inc . (NASDAQ: NASDAQ:CMRX) stock has reached a new 52-week high, touching $5.53 amidst a remarkable year of growth. With a market capitalization of $486 million, the stock has shown exceptional momentum, though InvestingPro analysis indicates it may be trading above its Fair Value. The biopharmaceutical company, known for its antiviral therapies, has seen its stock price surge over the past year, with an impressive 355.08% change. Investors have shown increased confidence in Chimerix’s pipeline and strategic initiatives, propelling the stock to levels not seen in the last year. Analyst price targets range from $7 to $12, suggesting potential upside, though technical indicators point to overbought conditions. This milestone underscores the company’s potential in the competitive pharmaceutical market and highlights the positive sentiment surrounding its future prospects. Get deeper insights and access to 17 additional ProTips with InvestingPro.
In other recent news, Chimerix announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application for dordaviprone, a potential treatment for recurrent H3 K27M-mutant diffuse glioma. The FDA has granted Priority Review status, setting a Prescription Drug User Fee Act target action date for August 18, 2025. This development is part of Chimerix’s efforts to address the limited treatment options for this aggressive form of brain cancer. Analyst firm H.C. Wainwright has reaffirmed its Buy rating on Chimerix, highlighting the potential for a third-quarter 2025 launch of dordaviprone. The drug has received several designations, including Fast-Track and Rare Pediatric Disease Designation, underscoring its potential impact. Additionally, TD Cowen mentioned Chimerix in its list of key biotech catalysts for 2025, noting the company’s submission for accelerated approval of dordaviprone. CEO Mike Andriole emphasized the company’s commitment to working swiftly with the FDA to expedite the review process. Investors are closely monitoring these developments as Chimerix progresses toward bringing dordaviprone to market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.